A chronic mouse model of Parkinson's disease has a reduced gait pattern certainty

Max J Kurz, Konstantinos Pothakos, Sakeena Jamaluddin, Melissa Scott-Pandorf, Chris Arellano, Yuen Sum Lau

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

The purpose of this investigation was to determine if a chronic Parkinson's disease mouse model will display less certainty in its gait pattern due to basal ganglia dysfunction. A chronic Parkinson's disease mouse model was induced by injecting male C57/BL mice with 10 doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (25 mg/kg) (MPTP) and probenecid (250 mg/kg) (P) over 5 weeks. This chronic model produces a severe and persistent loss of nigrostriatal neurons resulting in dopamine depletion and locomotor impairment. The control mice were treated with probenecid alone. Fifteen weeks after the last MPTP/P treatment, the mice were videotaped in the sagittal plane with a digital camera (60 Hz) as they ran on a motorized treadmill at a speed of 10 m/min. The indices of gait and gait variability were calculated. Stride length was significantly (p = 0.016) more variable in the chronic MPTP/P mice. Additionally, the chronic MPTP/P mice had a statistically less certain gait pattern when compared to the control mice (p = 0.02). These results suggest that variability in the gait pattern can be used to evaluate changes in neural function. Additionally, our results imply that disorder of the basal ganglia results in less certainty in modulating the descending motor command that controls the gait pattern.

Original languageEnglish (US)
Pages (from-to)39-42
Number of pages4
JournalNeuroscience Letters
Volume429
Issue number1
DOIs
StatePublished - Dec 11 2007
Externally publishedYes

Fingerprint

Gait
Parkinson Disease
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
Probenecid
Chronic Disease
Basal Ganglia Diseases
Basal Ganglia
Dopamine
Neurons

Keywords

  • Entropy
  • Gait
  • Locomotion
  • MPTP
  • Parkinson's disease
  • Probenecid
  • Variability

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Kurz, M. J., Pothakos, K., Jamaluddin, S., Scott-Pandorf, M., Arellano, C., & Lau, Y. S. (2007). A chronic mouse model of Parkinson's disease has a reduced gait pattern certainty. Neuroscience Letters, 429(1), 39-42. https://doi.org/10.1016/j.neulet.2007.09.060

A chronic mouse model of Parkinson's disease has a reduced gait pattern certainty. / Kurz, Max J; Pothakos, Konstantinos; Jamaluddin, Sakeena; Scott-Pandorf, Melissa; Arellano, Chris; Lau, Yuen Sum.

In: Neuroscience Letters, Vol. 429, No. 1, 11.12.2007, p. 39-42.

Research output: Contribution to journalArticle

Kurz, MJ, Pothakos, K, Jamaluddin, S, Scott-Pandorf, M, Arellano, C & Lau, YS 2007, 'A chronic mouse model of Parkinson's disease has a reduced gait pattern certainty', Neuroscience Letters, vol. 429, no. 1, pp. 39-42. https://doi.org/10.1016/j.neulet.2007.09.060
Kurz, Max J ; Pothakos, Konstantinos ; Jamaluddin, Sakeena ; Scott-Pandorf, Melissa ; Arellano, Chris ; Lau, Yuen Sum. / A chronic mouse model of Parkinson's disease has a reduced gait pattern certainty. In: Neuroscience Letters. 2007 ; Vol. 429, No. 1. pp. 39-42.
@article{4a3ab74e398a4cf78c8471ae45f15738,
title = "A chronic mouse model of Parkinson's disease has a reduced gait pattern certainty",
abstract = "The purpose of this investigation was to determine if a chronic Parkinson's disease mouse model will display less certainty in its gait pattern due to basal ganglia dysfunction. A chronic Parkinson's disease mouse model was induced by injecting male C57/BL mice with 10 doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (25 mg/kg) (MPTP) and probenecid (250 mg/kg) (P) over 5 weeks. This chronic model produces a severe and persistent loss of nigrostriatal neurons resulting in dopamine depletion and locomotor impairment. The control mice were treated with probenecid alone. Fifteen weeks after the last MPTP/P treatment, the mice were videotaped in the sagittal plane with a digital camera (60 Hz) as they ran on a motorized treadmill at a speed of 10 m/min. The indices of gait and gait variability were calculated. Stride length was significantly (p = 0.016) more variable in the chronic MPTP/P mice. Additionally, the chronic MPTP/P mice had a statistically less certain gait pattern when compared to the control mice (p = 0.02). These results suggest that variability in the gait pattern can be used to evaluate changes in neural function. Additionally, our results imply that disorder of the basal ganglia results in less certainty in modulating the descending motor command that controls the gait pattern.",
keywords = "Entropy, Gait, Locomotion, MPTP, Parkinson's disease, Probenecid, Variability",
author = "Kurz, {Max J} and Konstantinos Pothakos and Sakeena Jamaluddin and Melissa Scott-Pandorf and Chris Arellano and Lau, {Yuen Sum}",
year = "2007",
month = "12",
day = "11",
doi = "10.1016/j.neulet.2007.09.060",
language = "English (US)",
volume = "429",
pages = "39--42",
journal = "Neuroscience Letters",
issn = "0304-3940",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - A chronic mouse model of Parkinson's disease has a reduced gait pattern certainty

AU - Kurz, Max J

AU - Pothakos, Konstantinos

AU - Jamaluddin, Sakeena

AU - Scott-Pandorf, Melissa

AU - Arellano, Chris

AU - Lau, Yuen Sum

PY - 2007/12/11

Y1 - 2007/12/11

N2 - The purpose of this investigation was to determine if a chronic Parkinson's disease mouse model will display less certainty in its gait pattern due to basal ganglia dysfunction. A chronic Parkinson's disease mouse model was induced by injecting male C57/BL mice with 10 doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (25 mg/kg) (MPTP) and probenecid (250 mg/kg) (P) over 5 weeks. This chronic model produces a severe and persistent loss of nigrostriatal neurons resulting in dopamine depletion and locomotor impairment. The control mice were treated with probenecid alone. Fifteen weeks after the last MPTP/P treatment, the mice were videotaped in the sagittal plane with a digital camera (60 Hz) as they ran on a motorized treadmill at a speed of 10 m/min. The indices of gait and gait variability were calculated. Stride length was significantly (p = 0.016) more variable in the chronic MPTP/P mice. Additionally, the chronic MPTP/P mice had a statistically less certain gait pattern when compared to the control mice (p = 0.02). These results suggest that variability in the gait pattern can be used to evaluate changes in neural function. Additionally, our results imply that disorder of the basal ganglia results in less certainty in modulating the descending motor command that controls the gait pattern.

AB - The purpose of this investigation was to determine if a chronic Parkinson's disease mouse model will display less certainty in its gait pattern due to basal ganglia dysfunction. A chronic Parkinson's disease mouse model was induced by injecting male C57/BL mice with 10 doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (25 mg/kg) (MPTP) and probenecid (250 mg/kg) (P) over 5 weeks. This chronic model produces a severe and persistent loss of nigrostriatal neurons resulting in dopamine depletion and locomotor impairment. The control mice were treated with probenecid alone. Fifteen weeks after the last MPTP/P treatment, the mice were videotaped in the sagittal plane with a digital camera (60 Hz) as they ran on a motorized treadmill at a speed of 10 m/min. The indices of gait and gait variability were calculated. Stride length was significantly (p = 0.016) more variable in the chronic MPTP/P mice. Additionally, the chronic MPTP/P mice had a statistically less certain gait pattern when compared to the control mice (p = 0.02). These results suggest that variability in the gait pattern can be used to evaluate changes in neural function. Additionally, our results imply that disorder of the basal ganglia results in less certainty in modulating the descending motor command that controls the gait pattern.

KW - Entropy

KW - Gait

KW - Locomotion

KW - MPTP

KW - Parkinson's disease

KW - Probenecid

KW - Variability

UR - http://www.scopus.com/inward/record.url?scp=36148944310&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36148944310&partnerID=8YFLogxK

U2 - 10.1016/j.neulet.2007.09.060

DO - 10.1016/j.neulet.2007.09.060

M3 - Article

VL - 429

SP - 39

EP - 42

JO - Neuroscience Letters

JF - Neuroscience Letters

SN - 0304-3940

IS - 1

ER -